[go: up one dir, main page]

WO2024154061A1 - Compositions et procédés de stabilisation d'arn - Google Patents

Compositions et procédés de stabilisation d'arn Download PDF

Info

Publication number
WO2024154061A1
WO2024154061A1 PCT/IB2024/050424 IB2024050424W WO2024154061A1 WO 2024154061 A1 WO2024154061 A1 WO 2024154061A1 IB 2024050424 W IB2024050424 W IB 2024050424W WO 2024154061 A1 WO2024154061 A1 WO 2024154061A1
Authority
WO
WIPO (PCT)
Prior art keywords
nrn
rnn
nnn
nnr
rnr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2024/050424
Other languages
English (en)
Inventor
Eric Matthew Bennett
Amendra Fernando Hewa DEWAGE
Laura Lin LOHSE
Raghav Raj POUDYAL
Liliana Wroblewska
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Publication of WO2024154061A1 publication Critical patent/WO2024154061A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Definitions

  • w rnnmrrrr rrnnwnnnr :.n, r n. , mnr,nr .rvn n . , n ., n..rvn n n rn n .nxmnrmnnnn n n n w nm , nm “ nrn.xnmrr rnnnr. .xm nz. ”, wr nnr, ,n r,.
  • rnv,nr n “ ” rmmnx mr r xr n n n vrnrn nn’r n “ ” , r r n n’ r nrrr n.,nnm ,nz,- m: -n ., , : .rn n. r rrnr nnnn n n n mn rrmz- m nvrn n rn r rm . r n ,:- n rn mn.
  • n r n nn n.rxm, r mn -nnn mnnn ' rm vr r n w n, mn rr. r vrnn mn rv . . rm nn mnrnnr v m rrn w mrnnn,:n ,n nrrmnn r rnmm-r m mnrrnnnr m rmnn .wvm m r ,n wn nrnrn w nrnrn.
  • n.nr wr “nr”r nnv r vrr “nrn ” n “ ” n mmr rr.nmnn,rn,n mmr r v wnnw ,,, mn nn, nn,r m nn, m,rrr mmr r v rr. ,”r “n ”n n “mr,” “n n r n,nnrnnrx rr rwr n.
  • nnrm mrn “mr”n “mr”, “,vn w”rn “nmrrn” vn, “v”n “”, “nn”n m n “n ”r “nn nrmnn, “n ” rnvrn-nnnnn wnrnmrnnnm, n “nnn”n “nn” mnrr rmn n x nn r rmnr r rmn.
  • nm r rm “ r rnn nx “nnmrnn” m.”mmnmnn mn “nnxn nrm “n”nn”r wnrn nr mr m n nv rmr mr r wr “nn”nnrm nn, “n m r. mnnn,nm , wvrw r ”n “n ” “nn”n mnr rr “rnn.” , r mn m mnr,n n r r rmrnrn mr.
  • n “nmmn,” “nmmn,” “ mmn,” “rn,r” “m rmn,”m “mmnm,” “rnmmn,” “n n r r ,” “ mn”, “n ,” “n ,” “ ,” ,” r ,” “rn ,” “n n ,” “rr r “m ”rmnnr mn r r r,rrrr rnr rr.
  • rv w n “nr,”r “nr” r v m,r v nmrrnmrr wrm. rrrnxm,,nnr,rn,nr, n, n,m,r v nr.
  • nrr-m mn mn r n w r, mmmrnnrm rrrv,n v nnm mrv wrnr nnn n.nnrnn, mn n, wn rrmmr nrvrnnwnvnr mn.rnnnrrn nr w rnn m r v ′ , r mnrn r m v .n n-,′-w n n n , w rnn ,nnzm rv r mr r r r .
  • n,nrnv nn-n.rxm '- zn r'--m n nr n rn ,nnvr mn,n nrnv n - ,'-,'-,r rn m - rn..,-m rn..,-mxrn, ..,-m - rn,nr- n n-mnm.
  • n nnn nnnn rrmn r- ’ r mrrmr, r-n nmx n nr rnnrmrmx, nn rr mrn r m m -n nrnm mxn nrm r m. rrnv n , n , n , mr m ..,r n nnn n m nrrrmn,nn r.
  • r n n vnnr r rn rnn r rn rnmmr .,nr rmnnr r nnrnrn -, -, nmmmn, m m n. n m mrnr mr rnv rnv nr n. n. rn nv n nn n nn n rmnr rvv r. n m rnnnn ..rnr nn,r,mn,n n.
  • n n n nrnv nn.xmrnnm wnm,v mnnw mnmnnnn,-m- wnm, w n ,rxw nm,-,mrxw-wnm-, nrm rxw n *,- n , x n , - n , z-nn, n , -z-nnr ,-mnm--z- mnn- nmn,-n- z--z-nn,--nn,---nnr,r n+,- nn,-m-nnm,-- z-nn,---z---z- nn,-m-nnm -m-nn,---z--z- nn,-m-nnm -m-nn,-mx- m,,-m-nnm,,-m,
  • n rrnv nrrvv r ,,,r, r rr ..,-z n ,..,n nnrnn , n mn. nv m mn '- rr. '- rr m nnvrn nnrxrnnrn n nnn nrn nmnr, w rnn r wn-n n rm mr m m m . rr rmvn'-rrnnrn rmv r xm '-r nnnnn m wn n.
  • rvnn nn nrn n -.z rrrr mr rrr v '--' r rn ,rnv n n n n r n.rxm n nnzmrmw mnn rr'nw, m w--nn n rn n rnvrnnn nr r n n n '-- '. n- n . n mrnn , -mr nmn,n m n r r '-rmnnr'-nnr '-- n n '-rxr r.
  • n-nnnrr.nn m n m m n r rmn - rn r '-nn rnv n '- nr .rn nxrmnn n n n rvn n n nr-rnnnn.
  • nn-mnxm,rr,n rn,xrmrn mr, nv nnnnrnnrn r nn n r m rn nnn n.
  • n r r nrnrrr,rn. mn mxn, ,v ,r r r nr n ,x, r rrm n m r mr mn.mr,,rxm, nx rrr r nrr rnn r rm n m rmnn mnrm.
  • nr nnrmn mmnn nnr mn n n r mr rm n.rxm, nnr mn n m ,nr mrvn xnr rnrn , n r v n, , rn m, n, rn, nn, nnn,rmmrn mrn ,n n r,,r ,nr nrv nmv,n ,r, nnrrm.
  • rrr ....,, v x, xn rnn mrnn mr , x n rn , rn mn r n,rnr ,rn mnm , rn mn , x rn r,..,r mn , mn r n , x n x n , xm rn r, x r r..,r,n ,,xrn r r, n r r , vn-rrn, n,.., x nrnmn , m , m , , mrnrm r,, , , rmnmrm, r.
  • nznm r m,nrmnn nxmn,rr rrvvv mnnr,n,mrr nrmrvv,,nnxnn, rxmrvv,nxnrnrv,v,r nrmrvv,,nr rrvv.
  • n rn “r ” rr rn r .nmmmn, ”rrr r rr nn mmn, rr r.nmmmn, .nm nn r.nmm rr n mn, rr - r. r rvmmnmmmnn, rr m nn m v rnn.rnn, nn r mrrnrn .
  • nnnmnr m nn-mnr,r nn n, m,rm nnn-m,nn rn, ,- x rnnmnn.r , m mr n, m ,r m ,m ,r , r , , ,n , -nn ,r nnn,r,n ,rxn , nn , n , n mmrn.nmmmnn, .r r n mr nv r mmnrn.. nnr wnr mmrn.
  • n .nnrr rmmn mn n m n , m , nn n . m . m rr , .nrmmn .nmmmn, m r r. , m - nr rr m m n,mrnr nrr nnrr n m nn z, w n rr r n,rrrrrr nnr n n n m nn z,r .rxm, mn . rvmn r nrnr,n rrr n n rmn.., n m v ..
  • nr n rn nrnmn r m nn m r zn m n mr rvn m vn m, m vnnr n mrnn -r n n nr n r n m n . nrn,. nrvn m nn n nm , m r nr ′ n nr.
  • vrnn.nm , -m .,nn vrrn n.nm m n .n., m r rn mn nr mr m rn. rn,-m nn,- m n,- ′ nr mn n nn-rrrn , rr,r′nnnnnn n r nr. r nr. ,nrr ′nnnnnnnn rrrn ′n nr.nm , n nn- rr, nnrn nn,r m mr n.
  • n vr nnzmn mmrn nn nr n r n.nmnwxnn. nr,nrn w n r rn r n rnr n. n r vr rnn m m rn -n mn-- mrn. m n nr vvrr r-,n.n.,mrnmrn.rn mm , rn n n, r vr r n nrnv.
  • nnmnr n
  • nn--mnzmrnr wn z m r n rnrn,-mnnrnr n rr. rr nmrn rn mnn m m m . ′ n nrn n '-- m m rr m , w mrnr w r n nrn rrm m '- nmrrnr,rn mn m.
  • rrrnn mnnr ′ n r ′′r n nrn n m mrr.n .,n n mrr n r n nn n nr ,r rr m m-n, wn ′- n n n w ′- m n.nm , ′rmn rnm n,rxm,′rmn mn nnnn.x n n n n , r nm ,nn,-m-nn mr nn z-nn,-x-nn, ,′r-nn,- nnn.
  • nnnnnnn vvnrn′ nrr .nm n vn m n .nm
  • m nnr mr rn wn n .n nn rm m , m m nn , rn r,nnr mm nn . rrm w. n rnnnn nzm ′ n r mr , , m , m , wn: , m, mnnnn m r.n . m ,. m-n- r m , n r nn r n wn.
  • z nn rvr nnnn mn nz n .., n nw m nz ,..,rn v.n .n vr xr n nr mn n m n mn n.rn wmr.mmnn m nz ,..n m r n n nnmmnm n, ,rn n m n nz n,.., m .., . nn n m m r n m n n,..,nrrn-.
  • r r,.., r -n m rv nrn m nrr rnrnm,..n nr. n r r , nrn ,,r,n , v,nm, mmnrn , n, mr ,nr r mmrn rn m r r ,n mn wnmmrn w n, rrrnnvnr. nnn w nn v nr n n n n rn nr,n..nr r n n nm , m n ,nnn.
  • rnmr n n rm r nnrn :,,n. n : m r wnnnnm.mn-, wrn r n n w m nnn mnmn-,rrmrn: n m mmn,. n nr mrn wrn n n mr n . v n nnn n rn n m ’nnn m mmn r, wrn n m m nnn rnnmmn. m-,rrmmrnrn: ’.
  • nn n n w, wnrnr : nrn r r’- n wnn , w nnrnr,nrm ’n n r r r rrnn w nrn n n, - nn ’-nrn ,, n rnrmmr r n nn n :-,n-, n m-,-, nmnm-n.,n wrn n’-nrn rnnmr r nn :, rm m mmn,,-,-,n-.
  • n w n n rnn rn rn ', mm - r,n rnz m n n,rvrm rn, n 'n. n rn r w m rnm mn rn m ,r .
  • wrrvrm rw w n n. n w _rrr rnrn nrn,n n n n wn n nw n n nx wrnr, w n w nr _nrrr vn. rrnr w r rnn nn r nrn. nn m rn n r n n m , r r mnmn : nm. .
  • nrrr w nrn w mzn rmv nrn,nn m n r r rn, w n r rn. ,n r n m n r .
  • r mznr mm w m n nnn:n.nn rn,n nn r w rrxm n.wr nm rw nrn,r n rnrnn r r m n, n.n n, mz vn mznrm r n n m nwn n rn rn wr nv n n n n w n rn nnnnnn r, rn . r mzn, n nnn ,rn rrrn w.
  • n' nrn wr n w n rn mzn.nn n wr rn,n w rnnw rrnnrwn,nnnnn, mmn r .n v rn w w -. nznnn mnr rn w w . rwr nn.rn rrn ,w-r.
  • nr nwr r mrn w rnnn vr mznrn rnnn wnn mnn r .n m n r . vr n wr nrnrn.nrmnrn.mzn rn, n rm rn mzn w nr n :n rr v .. xrmn . : – n r m w r rr mrv n ,,n n nv n n. n ' mzn.
  • nr n rn vrxr n -n nmnnmnnnmxrrnn nnmnnr .' nr - wnnrvmnnvmr nr ..rxm, n.nrn,n n 'n' nnnv r' : - r m' n nm n,nxr rmr n mr r -- . n , wr n xr n, r w rn n vr ru -u:n.
  • xrrm wn r.n rmnnrrmn ' n n w rv n ,.., xr nn xrmn nr -r- m-_- __ r_rm.mnrn, xwrxmrn.n mnnr , nv nr rrm rn n w ,x r wxrnnr, w w nmr rr wr nrnrrrrrmm n n.
  • wrr w mxr n nvrn wr nnmmnnrxnrTMnn.nnnvnr rvnr w r m mrmn rnnn r w. nnr mnr r xr nr ,mr wmn w mr.mr , _ :, w v rrrmnnrn -xr n wn mrmrr rnnmxrr, wn m.r.
  • nrrmn wvrr mr wr wrr.nr nrnznnrmmnwnnw nmn m. r m nnr mmrn m vnr w nn.m- - -r -rmn nrm nw rn wr rmnn vn m n , mr nr r nnr mrnn .

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions et des procédés de stabilisation de molécules d'ARN. L'invention concerne également des régions 5' et 3' non traduites destinées à être utilisées dans des applications thérapeutiques et vaccinales.
PCT/IB2024/050424 2023-01-18 2024-01-17 Compositions et procédés de stabilisation d'arn Ceased WO2024154061A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363480445P 2023-01-18 2023-01-18
US63/480,445 2023-01-18
US202363610042P 2023-12-14 2023-12-14
US63/610,042 2023-12-14

Publications (1)

Publication Number Publication Date
WO2024154061A1 true WO2024154061A1 (fr) 2024-07-25

Family

ID=89723262

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2024/050424 Ceased WO2024154061A1 (fr) 2023-01-18 2024-01-17 Compositions et procédés de stabilisation d'arn

Country Status (1)

Country Link
WO (1) WO2024154061A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025074292A2 (fr) 2023-10-06 2025-04-10 Pfizer Inc. Compositions immunogènes
WO2025186725A2 (fr) 2024-03-06 2025-09-12 Pfizer Inc. Formulations de npl améliorées et leurs utilisations

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050147621A1 (en) * 2003-10-10 2005-07-07 Higgins Darren E. Use of bacterial 5' untranslated regions for nucleic acid expression
US20060148033A1 (en) * 2002-12-11 2006-07-06 Takara Bio Inc. Cold-induced expression vector
US20080312179A1 (en) * 2004-01-20 2008-12-18 Insight Biopharmaceuticals Ltd. High level expression of recombinant human erythropoietin having a modified 5'-UTR
US8519110B2 (en) 2008-06-06 2013-08-27 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College mRNA cap analogs
WO2014132064A2 (fr) * 2013-02-27 2014-09-04 University Of Newcastle Upon Tyne Cellules et procédés pour la synthèse d'acides gras
WO2022081764A1 (fr) * 2020-10-14 2022-04-21 RNAimmune, Inc. Vaccins contre le cancer à arnm pan-ras
WO2023283600A1 (fr) * 2021-07-08 2023-01-12 Fred Hutchinson Cancer Center Procédé d'analyse de la capacité des séquences d'acide nucléique cibles à avoir une incidence sur l'expression génétique

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148033A1 (en) * 2002-12-11 2006-07-06 Takara Bio Inc. Cold-induced expression vector
US20050147621A1 (en) * 2003-10-10 2005-07-07 Higgins Darren E. Use of bacterial 5' untranslated regions for nucleic acid expression
US20080312179A1 (en) * 2004-01-20 2008-12-18 Insight Biopharmaceuticals Ltd. High level expression of recombinant human erythropoietin having a modified 5'-UTR
US8519110B2 (en) 2008-06-06 2013-08-27 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College mRNA cap analogs
WO2014132064A2 (fr) * 2013-02-27 2014-09-04 University Of Newcastle Upon Tyne Cellules et procédés pour la synthèse d'acides gras
WO2022081764A1 (fr) * 2020-10-14 2022-04-21 RNAimmune, Inc. Vaccins contre le cancer à arnm pan-ras
WO2023283600A1 (fr) * 2021-07-08 2023-01-12 Fred Hutchinson Cancer Center Procédé d'analyse de la capacité des séquences d'acide nucléique cibles à avoir une incidence sur l'expression génétique

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
A. R. GENNARO: "Remington's The Science and Practice of Pharmacy", 2006, LIPPINCOTT, WILLIAMS & WILKINS
CAO ET AL., NATURE COMMUNICATIONS, vol. 12, 2021, pages 4138
FERREIRA ET AL., APPLIED BIOLOGICAL SCIENCES, vol. 110, no. 28, 2013, pages 11284 - 11289
HERNANDEZ ET AL., TRENDS IN BIOCHEMICAL SCIENCES, vol. 44, no. 12, 2019, pages 1009 - 1021
KORE ET AL., BIOORGANIC & MEDICINAL CHEMISTRY, vol. 21, 2013, pages 4570 - 4574
KOSE ET AL., SCI. IMMUNOL., vol. 4, no. 35, 2019, pages eaaw6647
LEPPEK ET AL., NAT COMMUN, vol. 13, 2022, pages 1536
LEPPEK ET AL., NAT REV MOL CELL BIOL, vol. 19, 2018, pages 158 - 174
LIM YITING ET AL: "Multiplexed functional genomic analysis of 5' untranslated region mutations across the spectrum of prostate cancer", NATURE COMMUNICATIONS, vol. 12, no. 1, 9 July 2021 (2021-07-09), XP093023532, Retrieved from the Internet <URL:https://www.nature.com/articles/s41467-021-24445-6> DOI: 10.1038/s41467-021-24445-6 *
ORLANDINI VON NIESSEN ET AL., MOL THER, vol. 27, no. 4, 2019, pages 824 - 836
SAMPLE ET AL., NATURE BIOTECHNOLOGY, vol. 37, 2019, pages 803 - 809
SEGAL ET AL., PNAS, vol. 116, no. 27, 2019, pages 13701
THERYAMIGORENA, CURR OPIN IMMUNOL., vol. 13, no. 1, 2001, pages 45 - 51
TRAINOR ET AL., SCIENTIFIC REPORTS, vol. 11, 2021, pages 2461
ZENG ET AL., ADV MATER, vol. 32, no. 40, 2020, pages e2004452
ZHANG ET AL., METHODS MOL BIOL, vol. 2586, 2023, pages 15 - 34

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025074292A2 (fr) 2023-10-06 2025-04-10 Pfizer Inc. Compositions immunogènes
WO2025186725A2 (fr) 2024-03-06 2025-09-12 Pfizer Inc. Formulations de npl améliorées et leurs utilisations

Similar Documents

Publication Publication Date Title
WO2024154061A1 (fr) Compositions et procédés de stabilisation d&#39;arn
Tapia et al. Production of high-titer human influenza A virus with adherent and suspension MDCK cells cultured in a single-use hollow fiber bioreactor
TWI698522B (zh) 細胞培養基之病毒過濾
SG194372A1 (en) Methods for cultivating cells, propagating and purifying viruses
WO2024144945A9 (fr) Procédés de production d&#39;aluminium à résistance élevée et articles en aluminium à résistance élevée produits à partir de celui-ci
AU2023408619A1 (en) Il-2 fusion protein
WO2025058551A1 (fr) Dispositif et procédés associés de débridement de plaies
WO2024223127A1 (fr) Procédés pour permettre le positionnement d&#39;un dispositif sans fil, nœud de réseau associé, nœud de réseau radio associé et dispositif sans fil associé
WO2024200062A1 (fr) Procédé pour permettre l&#39;atténuation d&#39;interférence au niveau d&#39;un dispositif sans fil, nœud de réseau associé et dispositif sans fil associé
EP4638473A1 (fr) Moyens et procédés pour cibler des condensats endogènes
WO2025168843A1 (fr) Peptides bactériens pour le traitement d&#39;une infection pneumococcique
WO2025054605A1 (fr) Amorces de pcr améliorées pour la virémie du sars-cov-2
US11999975B2 (en) Method for purifying an enveloped virus
WO2025202503A1 (fr) Vésicules extracellulaires portant des variants d&#39;épissage spécifiques du cancer
WO2025257416A1 (fr) Polypeptide tnpb amélioré et utilisation dans l&#39;édition génomique
WO2025262146A1 (fr) Prédiction de la probabilité d&#39;apparition d&#39;une ovulation après une fausse-couche
WO2024078908A1 (fr) Procédés de communication de liaison latérale, dispositifs sans fil associés et nœud de réseau associé
WO2025036886A1 (fr) Procédé pour résoudre un problème d&#39;optimisation
WO2025262144A1 (fr) Gestion de fausse couche pour des chances accrues d&#39;ovulation ultérieure
US10017735B2 (en) Cell culture of corneal endothelial cells
WO2025016964A1 (fr) Procédé de résolution d&#39;un problème de structure électronique sur la base d&#39;un calcul quantique contre-diabatique numérisé hybride
WO2024191359A1 (fr) Poudre hémostatique bioabsorbable à base de bore
WO2024165671A1 (fr) Protéines de fusion de la microglobuline ss2, polypeptides à chaîne lourde hla et inhibiteur de cd47-sirpa
CN104673761B (zh) 一种蓝耳病疫苗抗原纯化的方法
WO2024231578A1 (fr) Procédé de calcul quantique numérique-analogique de modèles fermion-boson dans des circuits supraconducteurs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24702194

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE